A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.

Antoinette R TanNancy ChanBrian F KieselMark N SteinRebecca A MossJyoti MalhotraJoseph AisnerMansi ShahMurugesan GounderHongxia LinMichael P KaneYong LinJiuping JiAlice ChenJan H BeumerJanice M Mehnert

Published in: Cancer chemotherapy and pharmacology (2021)

V and AC can be safely combined. Activity was observed in patients with metastatic breast cancer.

Keyphrases

metastatic breast cancer
low dose
high dose
drug delivery
cancer therapy